Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Stopped After enrolling approximately 1/2 of the trial participants, the rescues exceeded stopping criteria.

Conditions

• Macular Degeneration

Interventions

• DRUG: NT-503-3 ECT implantation
• DRUG: Eylea® injected intravitreally administered every 8 weeks

Sponsor

Neurotech Pharmaceuticals